Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma

Abstract

<b>Purpose:</b> PROTECT, a phase III, randomized, placebo-controlled study, evaluated pazopanib efficacy and safety in the adjuvant renal cell carcinoma setting. The relationship between pazopanib exposure (C_trough) and efficacy and safety was evaluated.<b>Patients and Methods:</b> Evaluable steady-state blood trough concentrations were collected from 311 patients at week 3 or 5 (early C_trough) and 250 patients at week 16 or 20 (late C_trough). Pazopanib pharmacokinetic (PK) data were analyzed via a population model approach. Relationship between C_trough or dose intensity and disease-free survival (DFS) was explored via Kaplan-Meier and multivariate analysis. Adverse events (AE) and AE-related treatment discontinuation proportions were summarized by C_trough quartiles.<b>Results:</b> Most (>90%) patients with early or late C_trough data started on 600 mg. Mean early and late C_trough overlapped across dose levels. Patients with higher early C_trough quartiles achieved longer DFS (adjusted HR, 0.58; 95% confidence interval, 0.42-0.82; <i>P</i> = 0.002). Patients achieving early or late C_trough >20.5 μg/mL had significantly longer DFS: not estimable (NE) versus 29.5 months, <i>P</i> = 0.006, and NE versus 29.9 months, <i>P</i> = 0.008, respectively. Dose intensity up to week 8 did not correlate with DFS, consistent with population PK model-based simulations showing overlapping pazopanib exposure with 600 and 800 mg doses. The proportion of AE-related treatment discontinuation and grade 3/4 AEs, with the exception of hypertension, was not correlated to C_trough<b>Conclusions:</b> In the adjuvant setting, higher pazopanib C_trough was associated with improved DFS and did not increase treatment discontinuations or grade 3/4 AEs, with the exception of hypertension. <i>Clin Cancer Res; 24(13); 3005-13. ©2018 AACR</i><i>See related commentary by Rini, p. 2979</i>.